Boston Scientific NYSE BSX perks up after hours on modest volume in apparent response to comments made today at JPM17 It indicated that it expects to launch its Lotus Edge heart valve in the U S in 2018 It added that it has identified a non safety problem with the valve in Europe but has a fix The company paused implantations in October in Europe due to issues with the valve s locking mechanism